104 T.W. Alexander Drive
64 articles with Precision BioSciences
Precision BioSciences Announces Formation of Scientific Advisory Board with Anderson, Kantarjian, Schinazi and Turtle
Precision BioSciences today announced the formation of its Scientific Advisory Board (SAB) with four key appointments: Kenneth C. Anderson, M.D., Hagop Kantarjian, M.D., Raymond Schinazi, Ph.D., D.Sc. and Cameron Turtle, MBBS, Ph.D.
Sharp brings a wealth of experience in financial management and corporate strategy in rare disease, gene therapy and oncology.
Precision BioSciences and Durham STEM Students Lead Launch of First Genome Editing Experiment Into Space
SpaceX Falcon 9 Delivering ARCUS Gene Editing to the International Space Station
Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy
Precision BioSciences and Servier today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for PBCAR0191, an allogeneic anti-CD19 CAR T therapy for B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).
Precision BioSciences gains rights to MaxCyte's cell engineering technology to develop next-generation, oncology-focused, cell therapies with Precision's ARCUS® genome-editing technology
The Baltimore Longitudinal Study of Aging was launched in 1958 by the National Institutes of Health. The idea was to follow and study the lives of healthy, active people over their lifetimes, rather than after they were dead.
Elo Life Systems has opened a new Australian location at the Queensland University of Technology (QUT), Gardens Point Campus in Brisbane.
Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
Gilead Sciences and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision’s proprietary genome editing platform, ARCUS.
Gilead Sciences had a lot of news lately. First off, Gilead and Belgium-based Galapagos NV announced results from their FINCH 2 Phase III clinical trial of filgotinib in adults with moderately-to-severely active rheumatoid arthritis.
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”
Precision Biosciences Announces Collaboration with University of Pennsylvania to Develop Genome Editing Therapeutics
Precision BioSciences today announced an expansion of their ongoing collaboration with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania.
Precision BioSciences closed on an oversubscribed Series B financing worth $110 million. The funds will be used to continue developing its ARCUS genome editing platform.
Precision BioSciences CSO Derek Jantz will present and join a panel discussion during the DIA (Drug Information Association) 2018 conference.
Precision BioSciences has announced a new name and brand identity for its food and agriculture business.
Precision BioSciences to Present In Vivo Gene Therapy and Ex Vivo Cancer Immunotherapy Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Precision BioSciences, the ARCUS genome editing company with novel product development programs in gene therapy, cancer immunotherapy and non-GMO food, will give three presentations at the upcoming ASGCT 21st Annual Meeting held in Chicago, Illinois, May 16-19, 2018.
ACEA Biosciences, a biotechnology company that develops high performance cell analysis instruments, hosted their 6th annual Cancer Immunotherapy Symposium focused on CAR-T cell and TCR therapy on April 14, 2018 at the W Hotel in Chicago, prior to the 2018 AACR Annual Meeting.